文献速递介入泌尿生殖腹部DSA

钇-90 经动脉放射栓塞治疗去势抵抗性前列腺癌肝转移

Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver.
PubMed 文献 · Acad Radiol · 2025-11-29

回顾性分析 7 例接受钇-90 经动脉放射栓塞(TARE)的去势抵抗性前列腺癌肝转移患者,RECIST 1.1 评估显示 3 例部分缓解、3 例疾病稳定,无靶病灶进展;中位总生存 16.2 个月,1 例发生 CTCAE 3 级疲乏。TARE 显示抗肿瘤活性且毒性可控,但最佳治疗时机尚不确定。

要点

  • RECIST 1.1 评估:6 例可评估患者中 3 例部分缓解、3 例疾病稳定,无靶病灶进展。
  • 中位靶病灶进展时间 2.3 个月,肝内进展 2.8 个月,肝外进展 7.0 个月。
  • 中位总生存 16.2 个月,1 例在术后 30 天内死亡,1 例 CTCAE 3 级疲乏。

核心结论

  • TARE 在去势抵抗性前列腺癌肝转移中显示抗肿瘤活性且毒性可控,但最佳治疗时机仍不确定。

研究设计与样本

  • 回顾性研究,纳入 2007 年至 2024 年 1 月期间接受钇-90 TARE 的 7 例去势抵抗性前列腺癌肝转移患者,采用 RECIST 1.1 评估靶病灶反应、Kaplan-Meier 法进行生存分析、CTCAE 5.0 评估术后 1 个月内不良事件。

诊断标准与关键数值

  • RECIST 1.1 评估最终影像反应:50%(n=3)达部分缓解,50%(n=3)为疾病稳定,无靶病灶进展;中位靶病灶剂量 95.0 Gy(范围 28.7-300.7 Gy),中位活度 1.2 GBq(范围 0.7-2.5 GBq)。

临床应用与阅片要点

  • 作者认为 TARE 在去势抵抗性前列腺癌肝转移中显示抗肿瘤活性且毒性可控,但最佳治疗时机仍不确定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: This study reports outcomes of patients undergoing transarterial radioembolization (TARE) utilizing yttrium-90 (Y90) for androgen-independent prostate cancer liver metastasis.

MATERIALS AND METHODS: A retrospective review was conducted for seven patients treated with TARE between 2007 and January 2024. Index tumor response was described through the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Survival analysis was calculated by the Kaplan-Meier method for index tumor, liver, extra-hepatic, and time-to-progression, as well as overall survival from day of TARE. Adverse events within one month of TARE were evaluated by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.

RESULTS: The median age of our cohort was 60.9 years (range, 52.3-79.2 years). The index tumor was treated with a median dose of 95.0 Gy (range, 28.7-300.7 Gy) and activity of 1.2 GBq (range, 0.7-2.5 GBq). Imaging follow up was completed for 86% (n = 6), with one early death. By RECIST criteria, 50% (n = 3) of patients achieved partial response and 50% (n = 3) of patients had stable disease as their final imaging responses. No index tumor progressed based on the RECIST criteria. Median progression was 2.3 (range, 1.3-6.9), 2.8 (range, 1.3-6.9), and 7.0 (range, 1.3-22.1) months for time-to-, hepatic, and extrahepatic progression, respectively. Median overall survival was 16.2 months (range, 1.0-93.2 months). One patient died within 30 days of the procedure. One patient reported CTCAE grade 3 effect: fatigue (n = 1).

CONCLUSION: TARE demonstrates antitumor activity and manageable toxicity in androgen-independent prostate cancer liver metastasis. However, optimal treatment timing remains uncertain.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Alzein MM, Gordon AC, Hussain MH, et al. Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver. Acad Radiol. 2025. PMID: 41320593. doi:10.1016/j.acra.2025.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。